Cover Image

干擾素的全球市場和開發平台分析 (2015年)

Global Interferon Market & Pipeline Analysis 2015

出版商 KuicK Research 商品編碼 328388
出版日期 內容資訊 英文 230 Pages
商品交期: 最快1-2個工作天內
Back to Top
干擾素的全球市場和開發平台分析 (2015年) Global Interferon Market & Pipeline Analysis 2015
出版日期: 2015年04月01日 內容資訊: 英文 230 Pages


本報告提供全球的干擾素的市場趨勢、臨床實驗進展相關分析、技術上的特性和主要的推動及阻礙市場要素、今後的市場趨勢預測、目前臨床實驗進展、主要的開發中產品 (共79種) 及已上市產品 (共37種) 的一覽、主要企業簡介等資訊彙整,為您概述為以下內容。

第1章 干擾素:簡介

第2章 干擾素的種類

第3章 干擾素治療藥的作用機制

第4章 全球干擾素市場概要

  • 目前市場方案
  • 干擾素的開發中產品的概要

第5章 全球干擾素市場動態

  • 有利的市場參數
  • 在企業化時的課題

第6章 全球干擾素市場未來展望

第7章 干擾素的臨床實驗平台產品:各國、各適應症、各Phase

  • 不明
  • 研究階段
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 登記前
  • 登記後

第8章 已上市干擾素醫藥品的研究:各企業、各適應症

第9章 臨床實驗中止、延期了的干擾素製劑的臨床實驗平台:各企業、各適應症

  • 沒有開發報告
  • 中止
  • 延期

第10章 競爭情形

  • Amgen
  • BaroFold
  • Bayer
  • Boehringer Ingelheim
  • GalaxoSmithKline
  • Genetech
  • Helix BioPharma
  • Intas Biopharmaceuticals
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Swedish Orphan Biovitrum



Interferons are small, low molecular weight proteins of varying sizes induced during attack by infectious agents like viruses. Investigators have found that they are highly variable in nature and have several subtypes due to which misunderstanding is easily created. Furthermore, they have synergistic effect in which interferons belonging to different classes have same effect on immune system due to sharing of common pathways. These facts gave emphasis on the development of classification system to organize, recognize, associate relationship and differentiate interferons from each other. Moreover, advent of genome sciences is allowing the investigators to look deeper into the DNA sequences that could be used to more clarity to existing classification system. In this way, investigators would be better informed and make suitable changes according to necessities of drug development program.

Interferon segment covers few diseases due to which they have modest market shares in pharmaceutical industry. Infectious diseases, few malignancies and Multiple Sclerosis are their major target group from which they generate revenues. Multiple sclerosis field is one of the highly developed segments which has numerous products and offer better performance than other therapeutics. In infectious diseases, they have significant effect and offers competition to vaccines which are one of the strongest pharmaceutical segments. In this segment, only for limited diseases they have very high pharmacological and commercialization potential due to which they are maintaining dominance in global market. Hepatitis and AIDS-associated disease is one such segment which generates significant revenues. On the other hand, cancer segment shows similar trend but their role in combinatorial therapy can't be neglected due to which they have become important for treating cancer. Some of them are first-line cancer therapeutics and it is imperative to increase their number to offer sustained competition. In this way, interferons have become indispensible part of several disease segments but limited number of products seems to be the major limiting factor despite their superior pharmacological benefits.

During disease incidence, particular types of interferons or associated molecules are produced in body to provide protection against infectious agents. Interferon based diagnostics are relatively new concept for the market and they are expected to be used for several diseases. Mostly they would be used for identifying infectious disease because of their immunological origin. As a result, they would have higher resolution, precision, accuracy and reproducibility of results. This technology is at nascent stages and it has to face severe competition from already existing diagnostics tests. Besides infectious disease, it could also be used for early cancer diagnosis due to which several lives could be saved. Diagnostically, they will have superior performance but their higher costs may cause some hinderance in their successful commercialization. With time, it is expected that the costs of developmental technology would decrease due to which more patients would be opting them to identify potential diseases.

In past few years, significant investments have been made in research and development segment to come forth with innovative products. It was observed that administration of interferons triggers a cascade of reactions in which some genes are activated. So, emphasis was given on developing higher order organization containing different hierarchy that could be used to extract information related to interferon genes. Knowledge of such genes could be utilized to develop innovative interferon based therapeutics for different diseases. Moreover, it could prevent the undue consumption of time and resources involved in screening of potential interferon candidates for drug development program. Due to their applicability in different diseases it is expected that they would be able to occupy major market shares across the globe. As a result, several therapeutic products are at different stages of clinical trials which will be introduced in global market in coming years.

“Global Interferon Market & Pipeline Analysis 2015” Report Highlights:

  • Introduction & Classification of Interferons
  • Interferon Clinical Pipeline Country, Indication & Phase
  • Interferon Clinical Pipeline: 79 Drugs
  • Majority Interferon Drugs in Preclinical Phase: 29 Drugs
  • Marketed Interferon Drugs: 37 Drugs
  • Marketed Interferon Drug Clinical Insight & Patent Analysis
  • Global Interferon Market Future Prospects

Table of Contents

1. Introduction to Interferon

2. Classification of Interferon

3. Mechanism of Interferon Therapeutics

4. Global Interferon Market Overview

  • 4.1. Current Market Scenario
  • 4.2. Interferon Pipeline Overview

5. Global Interferon Market Dynamics

  • 5.1. Favorable Market Parameters
  • 5.2. Commercialization Challenges

6. Global Interferon Market Future Prospects

7. Interferon Clinical Pipeline Country, Indication & Phase

  • 7.1. Unknown
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Clinical
  • 7.5. Phase-I
  • 7.6. Phase-I/II
  • 7.7. Phase-II
  • 7.8. Phase-III
  • 7.9. Preregistration
  • 7.10. Registered

8. Marketed Interferon Drug Insight by Company & Indication

9. Discontinued & Suspended & Interferon Drugs In Clinical Pipeline by Company Indication

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Suspended

10. Competitive Landscape

  • 10.1. Amgen
  • 10.2. BaroFold
  • 10.3. Bayer
  • 10.4. Boehringer Ingelheim
  • 10.5. GalaxoSmithKline
  • 10.6. Genetech
  • 10.7. Helix BioPharma
  • 10.8. Intas Biopharmaceuticals
  • 10.9. Merck
  • 10.10. Novartis
  • 10.11. Pfizer
  • 10.12. Roche
  • 10.13. Swedish Orphan Biovitrum

List of Figures

  • Figure 1-1: Major Types of Cytokine
  • Figure 1-2: Functions of Interferon
  • Figure 2-1: Classification of Interferons on the Basis of Types of Genes
  • Figure 3-1: General Mechanism of Interferons
  • Figure 3-2: Mechanism of Interferon Alfa-n3
  • Figure 3-3: Mechanism of Peginterferon Alfa-2a
  • Figure 3-4: Mechanism of Interferon Beta 1a
  • Figure 3-5: Mechanism of Interferon Alfa-2b
  • Figure 4-1: Interferons Pipeline Overview by Phase (%)
  • Figure 4-2: Interferons Pipeline Overview by Phase, (Number)
  • Figure 4-3: No Development Reported Interferons Pipeline Overview by Phase, (%)
  • Figure 4-4: No Development Reported Interferons Pipeline Overview by Phase, (Number)
  • Figure 4-5: Discontinued Interferons Pipeline Overview by Phase, (%)
  • Figure 4-6: Discontinued Interferons Pipeline Overview by Phase, (Number)
  • Figure 4-7: Suspended Interferons Pipeline Overview by Phase, (%)
  • Figure 4-8: Suspended Interferons Pipeline Overview by Phase, (Number)
  • Figure 5-1: Global Interferon Market Favorable Parameters
  • Figure 5-2: Global Interferon Market Commercialization Challenges
Back to Top